With a deal for its preclinical treatment for tackling dyslipidemia, KB-5359, thought to be imminent, Karo Bio AB strengthened its hand in partnering negotiations by completing a discounted rights offering that grossed SEK406 million (US$59.6 million). The cash is intended to fund the company through 2009 and into 2010. (BioWorld International)

With a deal for its preclinical treatment for tackling dyslipidemia, KB-5359, thought to be imminent, Karo Bio AB strengthened its hand in partnering negotiations by completing a discounted rights offering that grossed SEK406 million (US$59.6 million). The cash is intended to fund the company through 2009 and into 2010. (BioWorld International)

Noxxon Pharma AG added €37 million (US$50.3 million) to its coffers in a Series C round that will enable the company to take its two lead programs, NOX-E36 and NOX-A12, into development for lupus nephritis and diabetic retinopathy, respectively, through clinical proof of concept. (BioWorld International)

Noxxon Pharma AG added €37 million (US$50.3 million) to its coffers in a Series C round that will enable the company to take its two lead programs, NOX-E36 and NOX-A12, into development for lupus nephritis and diabetic retinopathy, respectively, through clinical proof of concept. (BioWorld International)